Mesenchymal Stem Cell Delivery of Oncolytic Viruses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering oncolytic viruses to cancer cells are limited by complex interactions with the tumor microenvironment and host immunity, leading to ineffective clinical outcomes.
Innovation Solution
Modified mesenchymal lineage precursor or stem cells, specifically STRO-1+ cells expressing certain markers, are used to deliver oncolytic viruses to cancer cells, leveraging their ability to home to tumors and repress inflammatory mediators, and are engineered to express connexins and capsid proteins for targeted virus delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oncolytic virus delivery methods are used, then virus can be delivered to cancer cells, but delivery effectiveness is limited by complex interactions with tumor microenvironment and host immunity
Solution Approach 1:
The patent uses mesenchymal stem cells as intermediary carriers to deliver oncolytic viruses to tumor cells. These stem cells naturally migrate to tumor sites and can efficiently transfer viruses upon contact, bypassing the complex immune and microenvironmental barriers that directly administered viruses face. The stem cell intermediary provides a protected delivery mechanism that exploits natural biological processes.
Solution Approach 2:
The mesenchymal stem cells utilize their inherent biological properties - specifically their natural tropism for tumor tissues and their ability to home to sites of injury or inflammation - to autonomously navigate to and deliver viruses at tumor locations. This self-directed delivery mechanism eliminates the need for complex external guidance systems or immune evasion strategies.
2Reliability
If mesenchymal stem cells are used as delivery vehicles, then targeting ability improves, but differentiation into less effective cells may occur
Solution Approach 1:
The patent modifies mesenchymal stem cells ex vivo before administration to enhance their virus delivery capacity and prevent unwanted differentiation. By pre-loading the stem cells with oncolytic viruses and potentially modifying their surface markers or genetic programming beforehand, the system ensures optimal delivery performance upon tumor contact, preventing the loss of effectiveness that would occur through natural differentiation processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the selective targeting and delivery of oncolytic viruses to cancer cells, reducing tumor growth while minimizing impact on mesenchymal lineage precursor or stem cells, thereby improving cancer treatment efficacy.
Implementation Method 1
The migration and adhesion capacity of mesenchymal lineage precursor or stem cells makes them particularly suitable for this purpose
Implementation Method 2
The migration and adhesion capacity of mesenchymal lineage precursor or stem cells makes them particularly suitable for this purpose
Implementation Method 3
contacting occurs under conditions permitting the mesenchymal lineage precursor or stem cell to form a gap junction with the cancer cell, whereby the oncolytic virus is delivered to the cancer cell by traversing the gap junction
Implementation Method 4
Another advantage of using mesenchymal lineage precursor or stem cells for delivery of oncolytic virus to cancer cells is their ability to repress inflammatory mediators such as TNF-alpha and/or IL-6
Data Source
AI summary
The present disclosure relates to cellular compositions that are modified to introduce an oncolytic virus. Such compositions may be used to treat cancer by delivering oncolytic virus to cancer cells.